Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1634 1641 1644
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18549665 | USES OF CD79B ANTIBODIES FOR AUTOIMMUNE THERAPEUTIC APPLICATIONS | Final Rejection | JANSSEN BIOTECH, INC. |
| 18572930 | ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18551679 | METHODS OF TREATING CANCER IN IMMUNOSUPPRESSED OR IMMUNOCOMPROMISED PATIENTS BY ADMINISTERING A PD-1 INHIBITOR | Non-Final OA | Sanofi Biotechnology |
| 18256565 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | Non-Final OA | Takeda Pharmaceutical Company Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy